ClinicalTrials.gg
Active, not recruitingNCT05334368DESTINYUpdated Oct 13, 2026

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

A Phase 3 interventional study of Depemokimab and Placebo in Hypereosinophilic Syndrome, sponsored by GlaxoSmithKline. Active, not recruiting at 60 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingNo longer in 5 countries+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.

The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.

Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.

02

Conditions studied

  • Hypereosinophilic Syndrome

Keywords

  • Depemokimab
  • Hypereosinophilic Syndrome
  • DESTINY
  • Monoclonal antibody
  • Anti-interleukin -5
03

In context

Hypereosinophilic Syndrome

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

This study's enrollment of 110 is above the median of 41 across 31 interventional studies indexed under Hypereosinophilic Syndrome.

Browse Hypereosinophilic Syndrome studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are greater than or equal (>=) 40 kilogram (kg) at Screening Visit 1.
  • Participants who have a documented diagnosis of HES prior to Visit 2.
  • A history of 2 or more HES flares within the past 12 months prior to Visit 1.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: a) woman of non- (WONCBP) Or b) woman of childbearing potential (WOCBP) and using a method that is highly effective, with a failure rate of less than (\<) 1 percentage (%).
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Participants with HES disease manifestations which in the opinion of the investigator may put the participant at unacceptable risk from study participation or confound interpretation of efficacy or safety data.
  • Participants with chronic or ongoing active infections requiring systemic treatment or a pre-existing parasitic infestation within 6 months prior to Visit 1.
  • Participants with a known immunodeficiency (e.g., [HIV]), other than that explained by the use of OCS or other therapy taken for HES.
  • Participants with a history of or current lymphoma.
  • Participants with current or previous history of cancer in remission for less than 5 years prior to Visit 1. Participants that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded.
  • Participants with a haematologic malignancy with hypereosinophilia in which HES is not the primary diagnosis, e.g., chronic myeloid leukaemia, myelodysplastic syndrome, chronic eosinophilic leukaemia-not otherwise specified.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment.
  • Participants who have severe or cardiovascular disease uncontrolled with standard treatment.
  • Participants with current diagnosis of vasculitis.
  • Hypereosinophila with no clinical symptoms and/or proof of organ dysfunction.
  • Clinical diagnosis of Eosinophilic granulomatosis with polyangiitis (EGPA).
  • Participants with an allergy/ intolerance to a monoclonal antibody or biologic, or any of the of the product.
  • Participants who have a previous documented failure with anti-interleukin (IL)-5/5R therapy.
  • Participants who have received monoclonal antibodies (mAb) within 30 days or 5 half-lives, whichever is longer, prior to Visit 1.
  • Participants who test positive for the FIP1L1-PDGFRα fusion gene.
  • corrected for heart rate according to Fridericia's formula (QTcF) ≥450 milliseconds (msec) or QTcF ≥480 msec for participants with Bundle Branch Block at Screening Visit 1.
  • Participants who are not responsive to OCS based on clinical response or blood eosinophil counts in the opinion of the Investigator.
  • Participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Depemokimab

    All participants in this arm will receive depemokimab.

    Drug: Depemokimab

  • Placebo comparator
    Placebo

    All participants in this arm will receive placebo.

    Other: Placebo

Interventions

  • Depemokimab will be administered.

  • OtherPlacebo

    Matching placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Frequency of HES flares

    A HES flare is defined as either: a HES-related clinical manifestation based on a physician documented change in clinical signs or symptoms resulting in the need for the following : An increase in the maintenance systemic corticosteroid dose by at least 10 mg/day (prednisone/prednisolone equivalent) for at least 5 days, and/or an increase in or addition of any cytotoxic and/or immunosuppressive HES therapy. OR 2 or more courses of blinded active oral corticosteroid (OCS) during the intervention period. The frequency of HES flares will be calculated for each participant as the number of unique starting dates for HES flares.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Time to first HES flare

    The time to first HES flare will be calculated from the date of first dose of study intervention and the start date of the HES flare. Time to the first HES flare will be assessed and reported in days.

    Time frame: Up to 52 weeks

  2. Number of participants with at least one HES flare during the 52-week study intervention period

    Time frame: Up to 52 weeks

  3. Change from Baseline to Week 52 in weekly average score of Brief Fatigue Inventory (BFI) item 3 (worst fatigue in last 24 hours)

    The BFI is a tool developed for the rapid assessment of fatigue severity for use in both clinical Screening and clinical trials. The BFI has 9 items. The participant should rate their average and worst fatigue levels over the previous 24 hours using a numeric rating scale anchored with 0 (no fatigue/interference) and 10 (as bad as you can imagine/completely interferes) numeric rating scales

    Time frame: Baseline and up to Week 52

07

Study locations

60 sites
  • GSK Investigational Site
    San Diego, California 92192, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    Columbus, Ohio 43212, United States
  • GSK Investigational Site
    Nashville, Tennessee 37208, United States
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Florida, 1602, Argentina
  • GSK Investigational Site
    La Plata, B1900, Argentina
  • GSK Investigational Site
    Mar del Plata, 7600, Argentina
  • GSK Investigational Site
    Quilmes, 1878, Argentina
  • GSK Investigational Site
    Garran, Australian Capital Territory 2606, Australia
  • GSK Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • GSK Investigational Site
    Blumenau, 89030-101, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21.941-913, Brazil
  • GSK Investigational Site
    Sorocaba, 18040-350, Brazil
  • GSK Investigational Site
    Ottawa, Ontario K1H 1E4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1X5, Canada
  • GSK Investigational Site
    Beijing, 100730, China
  • GSK Investigational Site
    Changsha, 410008, China
  • GSK Investigational Site
    Guangzhou, 510080, China
  • GSK Investigational Site
    Guangzhou, 510515, China
  • GSK Investigational Site
    Nanchang, 330006, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Suzhou, 215006, China
  • GSK Investigational Site
    Wuhan, 430022, China
  • GSK Investigational Site
    Brno-Bohunice, 625 00, Czechia
  • GSK Investigational Site
    Prague, 14059, Czechia
  • GSK Investigational Site
    Mannheim, 68167, Germany
  • GSK Investigational Site
    Catania, 95123, Italy
  • GSK Investigational Site
    Novara, 28100, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Aomori, 030-8553, Japan
  • GSK Investigational Site
    Chiba, 272-8516, Japan
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Hyōgo, 670-8540, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Tokyo, 105-8471, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    Wakayama, 641-8509, Japan
  • GSK Investigational Site
    Yamanashi, 409-3898, Japan
  • GSK Investigational Site
    Guadalajara, 44130, Mexico
  • GSK Investigational Site
    Monterrey, 64060, Mexico
  • GSK Investigational Site
    Veracruz, 94534, Mexico
  • GSK Investigational Site
    Chęciny, 26-060, Poland
  • GSK Investigational Site
    Lodz, 90-153, Poland
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 31281, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400124, Romania
  • GSK Investigational Site
    Gwangju, 61469, South Korea
  • GSK Investigational Site
    Jeonju, 561-712, South Korea
  • GSK Investigational Site
    Kangwondo, 26426, South Korea
  • GSK Investigational Site
    Seoul, 06351, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Seoul, 110-744, South Korea
  • GSK Investigational Site
    Seoul, 136-705, South Korea
  • GSK Investigational Site
    Seoul, 138-736, South Korea
  • GSK Investigational Site
    Suwon Kyunggi-do, 16499, South Korea
  • GSK Investigational Site
    Madrid, 28031, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Leicester, Leicestershire LE3 9QP, United Kingdom
08

References and documents

Related links

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2022 (actual). Primary completion is estimated for Oct 2027, 61 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Nov 2027 → Oct 2027 and completion Nov 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
Sep 6, 2022
Primary completionEst.
Oct 29, 2027was Nov 2027
CompletionEst.
Oct 29, 2027was Nov 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Sites
33 sites removed; no longer in Belgium, Denmark, Greece, Hong Kong and Israel
Show 33 removed
  • GSK Investigational Site · Boston, United States
  • GSK Investigational Site · Southfield, United States
  • GSK Investigational Site · Rochester, United States
  • GSK Investigational Site · Cincinnati, United States
  • GSK Investigational Site · Charleston, United States
  • GSK Investigational Site · Salt Lake City, United States
  • GSK Investigational Site · Brussels, Belgium
  • GSK Investigational Site · Guangzhou, China
  • GSK Investigational Site · Harbin, China
  • GSK Investigational Site · Hradec Králové, Czechia
  • GSK Investigational Site · Ústí nad Labem, Czechia
  • GSK Investigational Site · Odense C, Denmark
  • GSK Investigational Site · Bad Bramstedt, Germany
  • GSK Investigational Site · Athens, Greece
  • GSK Investigational Site · Rio Patras, Greece
  • GSK Investigational Site · Pokfulam, Hong Kong
  • GSK Investigational Site · Ramat Gan, Israel
  • GSK Investigational Site · Tel Aviv, Israel
  • GSK Investigational Site · Bologna, Italy
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Naples, Italy
  • GSK Investigational Site · Pavia, Italy
  • GSK Investigational Site · Treviso, Italy
  • GSK Investigational Site · Verona, Italy
  • GSK Investigational Site · Aomori, Japan
  • GSK Investigational Site · Kanagawa, Japan
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Granada, Spain
  • GSK Investigational Site · Madrid, Spain
  • …and 3 more on the registry record
Oct 13, 2026
Primary completion
Nov 24, 2027→Oct 29, 2027
Oct 13, 2026
Study completion
Nov 24, 2027→Oct 29, 2027
Oct 13, 2026
Enrollment
109 (estimated)→110 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    33 sites removed; no longer in Belgium, Denmark, Greece, Hong Kong and Israel
    Show 33 removed
    • GSK Investigational Site · Boston, United States
    • GSK Investigational Site · Southfield, United States
    • GSK Investigational Site · Rochester, United States
    • GSK Investigational Site · Cincinnati, United States
    • GSK Investigational Site · Charleston, United States
    • GSK Investigational Site · Salt Lake City, United States
    • GSK Investigational Site · Brussels, Belgium
    • GSK Investigational Site · Guangzhou, China
    • GSK Investigational Site · Harbin, China
    • GSK Investigational Site · Hradec Králové, Czechia
    • GSK Investigational Site · Ústí nad Labem, Czechia
    • GSK Investigational Site · Odense C, Denmark
    • GSK Investigational Site · Bad Bramstedt, Germany
    • GSK Investigational Site · Athens, Greece
    • GSK Investigational Site · Rio Patras, Greece
    • GSK Investigational Site · Pokfulam, Hong Kong
    • GSK Investigational Site · Ramat Gan, Israel
    • GSK Investigational Site · Tel Aviv, Israel
    • GSK Investigational Site · Bologna, Italy
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Naples, Italy
    • GSK Investigational Site · Pavia, Italy
    • GSK Investigational Site · Treviso, Italy
    • GSK Investigational Site · Verona, Italy
    • GSK Investigational Site · Aomori, Japan
    • GSK Investigational Site · Kanagawa, Japan
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Granada, Spain
    • GSK Investigational Site · Madrid, Spain
    • …and 3 more on the registry record
    Primary completion Nov 24, 2027→Oct 29, 2027
    Study completion Nov 24, 2027→Oct 29, 2027
    Enrollment 109 (estimated)→110 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05334368
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Sep 6, 2022
Primary completion
Oct 29, 2027 (estimated)
Completion
Oct 29, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion